In this regard, we can speculate that Dupilumab, a monoclonal antibody against the IL4 receptor, mediating both IL4 and IL13 pathways, was found effective in phase 2 randomized trial of EoE patients [45] by interfering with the IL13, rather than the IL4 signaling, justifying the absence of statistical significance in the IL4 modulation in our platform. The gene discussed is IL4; the disease is eosinophilic esophagitis.